Abstract | BACKGROUND: METHODS: Medical records of mRCC patients treated with investigational PD-1 or PD-L1 inhibitors at 4 academic institutions were reviewed. Patients who received subsequent treatment with TT were selected to collect outcome measures of subsequent TT. RESULTS: CONCLUSION:
|
Authors | Laurence Albiges, André P Fay, Wanling Xie, Katherine Krajewski, David F McDermott, Daniel Y C Heng, Charles Dariane, Guillermo DeVelasco, Renee Lester, Bernard Escudier, Toni K Choueiri |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 51
Issue 17
Pg. 2580-6
(Nov 2015)
ISSN: 1879-0852 [Electronic] England |
PMID | 26346135
(Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Ltd. All rights reserved. |
Chemical References |
- B7-H1 Antigen
- CD274 protein, human
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
- Vascular Endothelial Growth Factor A
- Receptors, Vascular Endothelial Growth Factor
- TOR Serine-Threonine Kinases
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- B7-H1 Antigen
(antagonists & inhibitors, metabolism)
- Carcinoma, Renal Cell
(drug therapy, metabolism, pathology)
- Female
- Humans
- Kidney Neoplasms
(drug therapy, metabolism, pathology)
- Male
- Middle Aged
- Molecular Targeted Therapy
(methods)
- Neoplasm Metastasis
- Programmed Cell Death 1 Receptor
(antagonists & inhibitors, metabolism)
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors, metabolism)
- Retrospective Studies
- Survival Analysis
- TOR Serine-Threonine Kinases
(antagonists & inhibitors, metabolism)
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, metabolism)
- Young Adult
|